Company research
Akero Therapeutics, Inc.
CIK 1744659Updated Sep 27, 2026
Securities
Historical securities (1)
AKRO · NASDAQ · equity · closed Dec 8, 2025AKRO price & chart
Historical security
This listing closed Dec 8, 2025. Live provider charts are shown only for current listings.
About the company
Akero Therapeutics is a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including metabolic dysfunction-associated steatohepatitis (MASH). Akero’s lead product candidate, efruxifermin (EFX), is currently being evaluated in three ongoing Phase 3 clinical studies: SYNCHRONY Histology in patients with pre-cirrhotic (F2-F3 fibrosis) MASH, SYNCHRONY Outcomes in patients with compensated cirrhosis (F4) due to MASH, and SYNCHRONY Real-World in patients with MASH or MASLD (metabolic dysfunction-associated steatotic liver disease). The Phase 3 SYNCHRONY program builds on the results of two Phase 2b clinical trials, the HARMONY study in patients with pre-cirrhotic MASH and the SYMMETRY study in patients with compensated cirrhosis due to MASH. Akero is headquartered in South San Francisco. Visit us at Akerotx.com and follow us on LinkedIn and X for more information.
In the news
SHAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger-HOUS, CRTAF, BRY, and AKRO News provided by Monteverde & Associates PC Nov 17, 2025, 20:30 ET Share this article Share to X Share this article Share to X NEW YORK , Nov. 17, 2025 /PRNewswire/ -- Class Action Attorney J ↗
Recent filings
SCHEDULE 13G/A - filed by JANUS HENDERSON GROUP PLC regarding Akero Therapeutics, Inc.
SCHEDULE 13G/A - filed by RTW INVESTMENTS, LP regarding Akero Therapeutics, Inc.
SCHEDULE 13G/A - filed by Deep Track Capital, LP regarding Akero Therapeutics, Inc.
15-12G filing
25-NSE - filed by Nasdaq Stock Market LLC regarding Akero Therapeutics, Inc.
Financials
FY 2024 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 825,886,000Source | 580,271,000Source | 356,570,000Source | 195,548,000Source |
| Property, Plant and Equipment, NetUSD | — | 18,000Source | 47,000Source | 90,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 340,238,000Source | 234,207,000Source | 249,773,000Source | 150,483,000Source |
| Assets, CurrentUSD | 770,380,000Source | 559,962,000Source | 355,173,000Source | 193,582,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 27,302,000Source | 9,952,000Source | 3,724,000Source | 5,324,000Source |
| Operating Lease, Right-of-Use AssetUSD | 755,000Source | 1,008,000Source | 1,242,000Source | 1,459,000Source |
| Other Assets, NoncurrentUSD | — | — | 108,000Source | 417,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 75,774,000Source | 44,965,000Source | 30,008,000Source | 26,439,000Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 7,000Source | 6,000Source | 5,000Source | 4,000Source |
| Additional Paid in CapitalUSD | 1,497,264,000Source | 1,040,200,000Source | — | — |
| Retained Earnings (Accumulated Deficit)USD | -826,156,000Source | -574,096,000Source | -422,337,000Source | -310,304,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 948,000Source | 270,000Source | 37,000Source | -27,000Source |
| Stockholders' Equity Attributable to ParentUSD | 750,112,000Source | 535,306,000Source | 326,562,000Source | 169,109,000Source |
| Additional Paid in Capital, Common StockUSD | 1,575,313,000Source | 1,109,126,000Source | 748,857,000Source | 479,436,000Source |
| Liabilities and EquityUSD | 825,886,000Source | 580,271,000Source | 356,570,000Source | 195,548,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 39,754,000Source | 19,128,000Source | 19,083,000Source | 25,128,000Source |
| Accounts Payable, CurrentUSD | 9,027,000Source | 7,038,000Source | 7,968,000Source | 6,706,000Source |
| Operating Lease, Liability, NoncurrentUSD | 529,000Source | 819,000Source | 1,079,000Source | 1,311,000Source |
| Additional Financial Items | ||||
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 797,829,000Source | 569,293,000Source | 351,449,000Source | 188,258,000Source |
cash flow · annual statements
| Line item | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -252,060,000Source | -151,759,000Source | -112,033,000Source | -100,777,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | 29,698,000Source | 21,497,000Source | 23,243,000Source | 10,054,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts PayableUSD | 2,008,000Source | -645,000Source | 968,000Source | 3,273,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -230,107,000Source | -145,367,000Source | -92,517,000Source | -79,681,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -109,708,000Source | -223,623,000Source | -63,825,000Source | 42,280,000Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 445,846,000Source | 353,316,000Source | 255,632,000Source | 602,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 340,238,000Source | 234,207,000Source | 249,881,000Source | 150,591,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 3,982,000Source | 2,483,000Source | 441,000Source | — |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 29,698,000Source | 21,497,000Source | 23,243,000Source | 10,054,000Source |
| Amortization of Debt Issuance Costs and DiscountsUSD | 607,000Source | 448,000Source | 204,000Source | — |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 797,829,000Source | 569,293,000Source | 351,449,000Source | 188,258,000Source |
| DepreciationUSD | 18,000Source | 29,000Source | 43,000Source | 41,000Source |
| Foreign Currency Transaction Gain (Loss), UnrealizedUSD | 19,000Source | 8,000Source | -16,000Source | -5,000Source |
| General and Administrative ExpenseUSD | 37,926,000Source | 31,072,000Source | 29,872,000Source | 19,127,000Source |
| Marketable Securities, Unrealized Gain (Loss)USD | 678,000Source | 233,000Source | 64,000Source | -24,000Source |
| Net Income (Loss) Attributable to ParentUSD | -252,060,000Source | -151,759,000Source | -112,033,000Source | -100,777,000Source |
| Operating Costs and ExpensesUSD | 285,423,000Source | 172,870,000Source | 115,156,000Source | 100,886,000Source |
| Proceeds from Issuance of Common StockUSD | 1,265,964,000Source | 818,900,000Source | 25,000,000Source | — |
| Proceeds from Stock Options ExercisedUSD | 13,145,000Source | 3,267,000Source | 5,016,000Source | 750,000Source |
income statement · annual statements
| Line item | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|
| Operating Income (Loss)USD | -285,423,000Source | -172,870,000Source | -115,156,000Source | -100,886,000Source |
| Net Income (Loss) Attributable to ParentUSD | -252,060,000Source | -151,759,000Source | -112,033,000Source | -100,777,000Source |
| Earnings Per Share, BasicUSD per share | -3.75Source | -2.89Source | -2.87Source | — |
| Earnings Per Share, DilutedUSD per share | -3.75Source | -2.89Source | -2.87Source | -2.89Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 67,136,772Source | 52,568,159Source | 38,984,772Source | — |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 67,136,772Source | 52,568,159Source | 38,984,772Source | 34,827,385Source |
| Additional Financial Items | ||||
| Common Stock, Dividends, Per Share, DeclaredUSD per share | 0Source | 0Source | 0Source | 0Source |
| General and Administrative ExpenseUSD | 37,926,000Source | 31,072,000Source | 29,872,000Source | 19,127,000Source |
| Interest and Other IncomeUSD | 38,031,000Source | 24,210,000Source | — | — |
| Interest ExpenseUSD | 4,668,000Source | 3,099,000Source | 739,000Source | — |
| Operating Costs and ExpensesUSD | 285,423,000Source | 172,870,000Source | 115,156,000Source | 100,886,000Source |
| Research and Development ExpenseUSD | 247,497,000Source | 141,798,000Source | 85,284,000Source | 81,759,000Source |